NCT01543035 - Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions

HIV Infection

Interventions

DRUG

stop statin and switch to an antiretroviral drug with less impact on lipid metabolism

Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin

Trial Locations (7)

1011

CHUV / Service des maladies infectieuses Médecine 2, Lausanne

1211

HUG /Division des Maladies infectieuses Unité VIH/SIDA, Geneva

2300

Hôpital Neuchâtelois - La Chaux-de-Fonds Service des Maladies infectieuses, La Chaux-de-Fonds

3010

Inselspital PKT2B / Poliklinik für Infektiologie, Bern

4031

Universitätsspital Basel Klinik für Infektiologie & Spitalhygiene, Basel

8091

Universitätsspital Zürich Division of Infectious Diseases and Hospital Epidemiology Department of Internal Medicine, Zurich

9007

Kantonsspital / Infektiologie und Spitalhygiene Departement Innere Medizin, Sankt Gallen

All Listed Sponsors

collaborator

Janssen-Cilag A.G., Switzerland

INDUSTRY

lead

Calmy Alexandra

OTHER